Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 65 of 5804
-
Engineered immune cells take aim at autoimmune kidney diseases
Disease control Recruiting nowThis study is a single-center, open-label, dose-escalation exploratory clinical trial, expected to enroll 6 to 12 participants. It will use a BOIN (Bayesian Optimal Interval) design for dose escalation, with four predetermined dose groups (0.3×10\^6 cells/kg, 1.0×10\^6 cells/kg, …
Phase: PHASE1 • Sponsor: Nanjing University School of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Custom-Made cancer vaccine shows promise in early trial
⭐️ VACCINE ⭐️ Recruiting nowThis clinical trial is studying the safety and efficacy of a personalized cancer vaccine called a neoantigen peptide vaccine in patients with solid tumors. These vaccines are custom-made for each patient using specific mutations (neoantigens) found in their own tumor. The goal is…
Phase: PHASE1, PHASE2 • Sponsor: Seqker Biosciences, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 26, 2026 00:00 UTC
-
New drug sabirnetug aims to slow Alzheimer's decline
Disease control OngoingThe primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Phase: PHASE2 • Sponsor: Acumen Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Gene therapy trial aims to tame severe seizures in kids with dravet syndrome
Disease control OngoingWAYFINDER is a Phase 1/2 study in Australia to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged 6 to \<84 months. The study follows an open-label, dose-escalation design.
Phase: PHASE1, PHASE2 • Sponsor: Encoded Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Two-Drug combo aims to stop lung cancer recurrence after surgery
Disease control OngoingThe combination of neoadjuvant immunotherapy plus chemotherapy has recently been shown to improve survival outcome compared to chemotherapy alone and was recently approved for resectable non-small cell lung cancer (NSCLC). Despite so, recurrence risk of NSCLC after surgical resec…
Phase: PHASE2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Triple-Negative breast cancer: SKB264 trial launches
Disease control Recruiting nowThe aim of the study is to evaluate the efficacy and safety of SKB264 as first-line treatment for patients with unresectable recurrent or metastatic triple-negative breast cancer (TNBC) whose tumors do not express programmed cell death ligand 1 (PD-L1) or in patients with PD-L1 p…
Phase: PHASE3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New hope for ovarian cancer: targeted drug R-DXd enters key trial
Disease control Recruiting nowThis study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Phase: PHASE2, PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Choice of Long-Acting HIV prevention could transform care for young people in rural south africa
Prevention Recruiting nowThe goal of this hybrid (1a) Cluster Randomised Controlled Trial phase 3B trial is to evaluate the effectiveness and implementation of offering a choice of HIV Pre-Exposure Products (PrEP) through community-based sexual and reproductive health services, on PrEP uptake and retenti…
Phase: PHASE3 • Sponsor: Africa Health Research Institute • Aim: Prevention
Last updated Jul 11, 2026 00:00 UTC
-
Supercharged immune cells take on tough leukemia
Disease control Recruiting nowParticipants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy that participants will receive …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Double-Barreled attack: Gene-Edited stem cells and CAR T-Cells take on tough leukemia
Disease control Recruiting nowThe purpose of this study is to provide a new type of treatment for AML. This treatment combines a new type of stem cell transplant along with treatment using chimeric antigen receptor (CAR) T cells that have been engineered to recognize and attack your AML cells. The first trea…
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug aims to stop lung cancer relapse after Chemo-Radiation
Disease control OngoingThe primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid tumors v1.1 (RECIST 1.1) and on prolonging overall…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental drug aims to preserve arm and lung function in boys with advanced duchenne
Disease control Recruiting nowThis is a randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety, and tolerability of givinostat in non-ambulant male paediatric (aged 9 to \<18 years) patients with DMD. 138 patients will be randomised 2:1 to givinostat or placebo and wi…
Phase: PHASE3 • Sponsor: Italfarmaco • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could a single infusion of modified immune cells tame lupus?
Disease control Recruiting nowRESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Engineered donor cells take on childhood leukemia in first human test
Disease control Recruiting nowThis is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz (CD19-CAR.CD45RA- negative T-cells) for the treatment of patients ≤ 21 years old with…
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental gene therapy aims to halt rare childhood disease
Disease control OngoingA non-randomized, open-label, Phase 1/2/3 study of a single intracerebroventricular (ICV) administration of a gene replacement therapy (GS-100) in participants who are 2 to 18 years old with NGLY1 Deficiency.
Phase: PHASE3 • Sponsor: Grace Science, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill zongertinib takes on HER2 lung cancer in major trial
Disease control OngoingThis study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer.…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New combo therapy takes on deadly brain cancer
Disease control OngoingThe goal of this clinical trial is to test a combined therapy approach (allogeneic cytomegalovirus \[CMV\]-specific T cells and pembrolizumab) in patients with brain cancer. The type of brain cancer being studied is glioblastoma multiforme/astrocytoma grade 4. The purpose of par…
Phase: PHASE1, PHASE2 • Sponsor: Queensland Institute of Medical Research • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could a single dose of psilocybin help people break free from opioid addiction?
Disease control Recruiting nowThis study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care outpatient buprenorphine treatment for Opioid use disorder (OUD). The participants will have pr…
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Gene therapy vs. standard care: new study tracks Long-Term outcomes in duchenne patients
Disease control ENROLLING_BY_INVITATIONThis is a multicenter, prospective, observational Phase 4 study including a post marketing safety requirement, designed to collect both medical history data and prospective data on Duchenne muscular dystrophy (DMD) treatment outcomes in participants receiving delandistrogene moxe…
Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a phone app stop suicide? new trial aims to find out
Disease control Recruiting nowThe primary aim of the project is to test the efficacy of BCBT delivered via a digital platform (i.e., smartphone) to Servicemembers with recent suicidal ideation and/or suicide attempts presenting to primary care clinics. Given existing challenges of scaling empirically-supporte…
Phase: NA • Sponsor: University of Memphis • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC